It reveals a potentially new regulatory mechanism for the control of Pgrn levels and, consequently, its associated neurobiology in the brain, providing insight into the pathophysiology and the therapeutic development of PGRN-associated neurodegenerative diseases. This evidence concerns the gene GRN and neurodegenerative disease.